Actively Recruiting
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Led by Treeline Biosciences, Inc. · Updated on 2025-10-10
50
Participants Needed
5
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
CONDITIONS
Official Title
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years of age at the time of signing the informed consent form.
- Peripheral T-cell lymphoma (PTCL) relapsed after or not responded to at least one prior systemic treatment. Participants with Anaplastic large cell lymphoma (ALCL) must have received prior brentuximab vedotin treatment.
- PTCL subtypes include nodal T-follicular helper (TFH) cell lymphoma angioimmunoblastic, follicular helper T-cell lymphoma angioimmunoblastic type, nodal TFH cell lymphoma follicular type, nodal TFH cell lymphoma not otherwise specified, PTCL not otherwise specified, anaplastic large-cell lymphoma ALK positive, and ALK negative.
- Relapsed or refractory cutaneous T-cell lymphoma (CTCL) relapsed after or not responded to at least two prior systemic treatments, including Sezary syndrome and Mycosis fungoides.
- Measurable disease at study entry.
- Freshly biopsied or archival tissue available.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Adequate organ function.
- Participants must accept and follow the pregnancy prevention plan.
You will not qualify if you...
- Prior systemic anti-cancer treatment within 5 half-lives or 4 weeks before starting the study treatment.
- Allogeneic stem cell transplant within 90 days or autologous stem cell transplant within 60 days before study intervention.
- Any significant acute or chronic medical illness, active or uncontrolled infection, or laboratory abnormalities that pose an unacceptable risk.
- Current or past central nervous system (CNS) involvement.
- Pregnant or lactating women.
- Unable to swallow tablets.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Stanford Cancer Institute
Stanford, California, United States, 94305
Actively Recruiting
2
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
3
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
4
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
5
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
Actively Recruiting
Research Team
T
Treeline Clinical Operations
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here